

RESEARCH AT THE NYU VACCINE CENTER

TO SERVE — TO TEACH — TO DISCOVER
HERE AT THE VACCINE CENTER

COVID- 19 has taught us that we are in a constant fight against the SARS-CoV-2 virus and its variants, and likely against future emerging infectious diseases. The Vaccine Center was designed to provide rapid responsiveness and preparedness for these recurring events. The most effective way to defeat these viruses is to strengthen our immune systems through vaccinations.

“I want to say thank you to every single study volunteer who participated in a clinical trial with us.

The new knowledge gained through your heroic participation is invaluable and is helping us fight these viruses,” said Dr. Mark Mulligan, director of the Vaccine Center.



Dr. Mark Mulligan, in front of Dr. Anthony Fauci mural, in Manhattan's East Village.

IN THE NEWS

Heterologous SARS-CoV-2 Booster Vaccinations

This year, the NYU Vaccine Center (at our Bellevue Hospital and NYU Long Island sites) participated in the NIH-funded "Mix and Match" study—a SARS-CoV-2 Vaccine Booster Trial—the results of which directly influenced the recent CDC guidelines on booster vaccines.

[READ MORE>](#)

For more information, visit our website

<https://med.nyu.edu/centers-programs/vaccine/>


RECENT PUBLICATIONS FROM THE NYU VACCINE CENTER

How prior history of COVID-19 influences adaptive immune responses to mRNA vaccination

Science Translational Medicine • December 7, 2021

Drs. Herati and Mulligan's teams compared the COVID-19 vaccine immune responses of participants who had experienced COVID-19 infection to those who did not.

Post-dose 1 Pre-dose 2 Post-dose 2



Virus neutralization assay with plasma from a COVID-19-naive participant (virus stained in green, cells in blue).

Their work stresses the relevance of immunological history for understanding COVID-19 vaccine immune responses and has important implications for personalizing mRNA vaccination regimens and the deployment of booster shots.


[READ MORE>](#)

AZD1222 COVID-19 Vaccine Safety and Efficacy

New England Journal of Medicine • September 29, 2021

Our five sites (NYU Manhattan, NYU Brooklyn, NYU Long Island, Bellevue Hospital, and the VA) participated in an international double-blind, randomized, placebo-controlled, phase 3 clinical trial, to investigate vaccine efficacy, and immunogenicity of two doses of AZD 1222. The data from this trial showed that AZD 1222 was safe and efficacious in preventing COVID-19 in large, diverse, at-risk populations.

[READ MORE>](#)



TEAM HIGHLIGHT: TAMIA DAVIS, NP

Tamia is a native New Yorker. She received her Bachelor's and her Master's degrees in nursing- both with honors- from Hunter College. She joined the Vaccine Center research team as a Nurse Practitioner in September 2020. Loved by all staff and participants, she is based at our Manhattan NYU Clinic.

Her favorite destination is the island of Aruba, she loves it so much she could retire there.



Tamia Davis, RN, MSN, AGPCNP-B.

SPREAD THE WORD

Yellow Fever

The NYU Langone Vaccine in Manhattan is taking part in a phase 2 yellow fever vaccine trial sponsored by Sanofi Pasteur comparing a research yellow fever vaccine to an FDA licensed vaccine.

[Learn more>](#)

Stop Flu NYU

This study is being conducted to study the body's response to the seasonal influenza vaccination and to learn about the protection from infection with influenza.

[Learn more>](#)

MomiVax

The NYU Langone Vaccine Center's sites in Manhattan and Brooklyn are taking part in a NIAID funded, observational study for people who are pregnant or who recently had a baby and have either received or are scheduled to receive a COVID- 19 vaccine.

[Learn more>](#)

Pediatric and adults volunteers needed in upcoming Vaccine Trials.

Learn more: <https://redcap.link/parvax>